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Idiopathic Pulmonary Fibrosis (IPF) is a progressive disease of unknown etiology. The diag-
nosis is based on the identification of a pattern of usual interstitial pneumonia either by high
resolution computed tomography and/or histology. However, a similar pattern can be
observed in other fibrotic lung disorders, and precise diagnosis remains challenging. Studies
on biomarkers contributing to the differential diagnosis are scanty, and still in an exploratory
phase. Our aim was to evaluate matrix metalloproteinase (MMP)-28, which has been impli-
cated in abnormal wound healing, as a biomarker for distinguishing IPF from fibrotic non-
IPF patients.
Methods
The cell localization of MMP28 in lungs was examined by immunohistochemistry and its
serum concentration was measured by ELISA in two different populations. The derivation
cohort included 82 IPF and 69 fibrotic non-IPF patients. The validation cohort involved 42
IPF and 41 fibrotic non-IPF patients.
Results
MMP28 was detected mainly in IPF lungs and localized in epithelial cells. In both cohorts,
serum concentrations of MMP28 were significantly higher in IPF versus non-IPF (mostly with
lung fibrosis associated to autoimmune diseases and chronic hypersensitivity pneumonitis)
and healthy controls (ANOVA, p<0.0001). The AUC of the derivation cohort was 0.718 (95%
CI, 0.635–0.800). With a cutoff point of 4.5 ng/mL, OR was 5.32 (95%CI, 2.55–11.46), and
sensitivity and specificity of 70.9% and 69% respectively. The AUC of the validation cohort
was 0.690 (95%CI, 0.581–0.798), OR 4.57 (95%CI, 1.76–12.04), and sensitivity and specific-
ity of 69.6% and 66.7%. Interestingly, we found that IPF patients with definite UIP pattern on
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HRCT showed higher serum concentrations of MMP28 than non-IPF patients with the same
pattern (7.8±4.4 versus 4.9±4.4; p = 0.04). By contrast, no differences were observed when
IPF with possible UIP-pattern were compared (4.7±3.2 versus 3.9±3.0; p = 0.43).
Conclusion
These findings indicate that MMP28 might be a useful biomarker to improve the diagnostic
certainty of IPF.
Introduction
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, aging-related lung disease of
unknown etiology.[1–3] The prognosis is usually poor, with a median survival time of 2 to 5
years.[1]
The diagnosis of IPF requires the exclusion of recognizable cause of interstitial lung disease
(ILD) and identification of a pattern of usual interstitial pneumonia (UIP) either on high-reso-
lution computed tomography (HRCT) or by histology. In the appropriate clinical setting, the
presence of UIP pattern on HRCT is sufficient to confirm the diagnosis of IPF. However, the
precise diagnosis may be extremely difficult because other chronic fibrotic lung disorders such
as ILD associated to connective tissue diseases (primarily rheumatoid arthritis) and chronic
hypersensitivity pneumonitis (cHP) may exhibit a UIP-like pattern.[4,5] Unfortunately, bio-
markers that may help to distinguish IPF from fibrotic non-IPF ILDs are scanty.
Matrix metalloproteinases (MMPs) are a family of zinc-dependent matrixins that partici-
pate in the degradation of the extracellular matrix but also process a variety of mediators such
as growth factors, cytokines and chemokines.[6] Importantly, upregulation of several MMPs
has been identified in IPF lungs, and two of them, MMP7 and MMP1 have been found
increased in sera, and proposed (mainly MMP7) as putative biomarkers for the differential
diagnosis.[7–11] Furthermore, it was recently reported that a biomarker index conformed by
surfactant protein D (SP-D), MMP7, and osteopontin enhanced diagnostic accuracy in
patients with IPF compared with those with non-IPF ILD.[12]
MMP28 is the latest member of the MMPs family and structurally belongs to the MMP19
subfamily,[13] which we revealed as over-expressed in IPF lung epithelium.[8] MMP28 has
been reported upregulated in some pathologic conditions such as osteoarthritis,[14] gastric can-
cer[15] and certain heart conditions such as acute myocardial infarction and unstable angina.
[16,17] Recently, we have shown that MMP28 is upregulated in IPF and that MMP28 deficient
mice are protected from bleomycin-induced lung fibrosis suggesting a profibrotic role.[18]
Based on these findings we decided to explore the putative role of MMP28 as a diagnostic
biomarker in IPF. For this purpose, we examined the lungs by immunohistochemistry and
measured this enzyme in blood serum from Mexican patients with IPF, fibrotic ILD associated
to autoimmune diseases, chronic hypersensitivity pneumonitis and healthy control subjects
(derivation cohort) and in similar groups from Spain (validation cohort).
Patients and methods
Study population
Two cohorts of IPF patients were included, one from the Instituto Nacional de Enfermedades
Respiratorias, Mexico (INER; n = 82, derivation cohort) and the other from the Unit of
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Interstitial Lung Diseases of Bellvitge Hospital, Barcelona (n = 42; validation cohort). The diag-
nosis of IPF was established according to international criteria based on the presence of usual
interstitial pneumonia either by HRCT and/or lung morphology.[1] Blood samples were
obtained at the time of diagnosis, without previous treatment, and the sera were frozen until
use.
In the Mexican cohort, the fibrotic non-IPF group consisted of patients with Rheumatoid
Arthritis interstitial lung disease (RA-ILD n = 18), Sjögren Syndrome interstitial lung disease
(SS-ILD n = 5), or chronic hypersensitivity pneumonitis (cHP n = 46). Thirty-six age-matched
healthy subjects were evaluated as controls.
The Spanish cohort included 41 non-IPF patients (nonspecific interstitial pneumonitis
(NSIP), cHP, Scleroderma interstitial lung disease (Scl-ILD) and RA-ILD) and 11 healthy
controls.
A multidisciplinary diagnostic team reviewed all final IPF and non-IPF diagnoses. The
review boards of both, Instituto Nacional de Enfermedades Respiratorias "Ismael Cosio Ville-
gas", and University Hospital of Bellvitge, approved the study and all patients signed informed
consent to participate in the study.
Immunohistochemistry
We examined the localization of MMP28 in 8 IPF, 5 HP and 5 normal lungs. Immunohisto-
chemical analysis was performed as described.[8] Briefly, formalin-fixed, paraffin-embedded
lung tissues were obtained from biopsy or autopsy specimens of individuals with IPF or HP
and controls in compliance with institutional review board-approved protocols. Three μm
lung sections were deparaffinized, rehydrated and incubated for 30min in 3% H2O2. After
antigen unmasking using citrate buffer, and blocking with 2% of normal sheep serum in PBS,
lung sections were incubated for 18 h at 4˚C with anti-MMP28 rabbit polyclonal antibody
(Novus Biologicals NBP2-17314, 1:100) diluted in PBS with 2% of serum. Sections were then
incubated with a secondary biotinylated anti-immunoglobulin antibody followed by horserad-
ish peroxidase-conjugated streptavidin (Biogenex). 3-Amino-9-ethyl-carbazole in acetate
buffer containing 0.05% H2O2 was used as substrate. The sections were counterstained with
hematoxylin and mounted with Cristal Mount. The primary antibody was replaced by nonim-
mune serum for negative control slides. Analysis was performed under a Nikon microscope
with NIS-Elements AR software.
Enzyme-linked-immunosorbent assay
MMP28 concentration in serum was determined by ELISA specific for human MMP28 follow-
ing the instructions of the manufacturer (SEB999Hu, Clone-Cloud Corporation, USCN,
PRC). In addition, in the Mexican cohort, MMP7 was also measured by ELISA (DMP700,
R&D). In both cohorts, the same person (MM) did the measurement.
Statistical analysis
All analyses were performed using Excel 2011 Version 14.7.1, Stata/SE 12.0 for Mac software
and Graph Pad Pris 4. To compare IPF versus non-IPF patients, samples were analyzed by
U-Mann Whitney. IPF, non-IPF and controls were compared by one-way ANOVA with
Dunn’s post-tests. p<0.05 was considered of significance. Receiver-operating characteristics
(ROC) analysis was used to evaluate sensitivity, specificity and to determine the optimal cut
point of MMP28 for differential diagnosis; the area under the curve (AUC) from unadjusted
ROC analysis was calculated. We used Odds Ratios (ORs) to determine an association for dif-
ferential diagnosis between IPF and non-IPF patients. The relationship between patient
MMP28 as biomarker for IPF diagnosis
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diagnosis and biomarker was explored using adjusted logistic regression. Demographic [age,
sex, smoking status (self-reported and categorized into current, former, or never)] and func-
tional (baseline FVC and DLCO) data were used as potential confounding factors. Addition-
ally, concentrations of MMP28 were correlated with pulmonary functional tests, diffusing




This study included 124 IPF patients, 110 non-IPF patients [primarily cHP and fibrotic
CTD-ILD (fibrotic NSIP and UIP-like patterns)] and 47 age-matched controls from two
cohorts (Mexican controls: 66 ± 8 years; Spanish controls 67±9 years). The derivation cohort
was examined in patients living in Mexico City at 2440 meters altitude. The validation cohort
was evaluated in Barcelona at sea level. The demographic characteristics and functional abnor-
malities of the two populations at the time of diagnosis are summarized in Tables 1 and 2, and
included in extenso in S1 File. In both Mexican and Spanish cohorts, there was a gender differ-
ence (female predominance in the non-IPF cohort) and more smokers in the IPF group. IPF
patients from the Mexican cohort were older than non-IPF and exhibited lower oxygen satura-
tion at rest.
Immunohistochemical localization of MMP28
MMP28 cell localization was examined by immunohistochemistry. In IPF lungs, the immuno-
reactive protein revealed a strong positive labeling mainly in alveolar epithelial cells while a
weaker staining was detected in HP, localized mainly in interstitial cells (Fig 1). No immuno-
reactive protein was noticed in the control lungs.
MMP28 is increased in serum of IPF patients compared with non-IPF
patients
MMP28 concentration in serum from patients and controls of both cohorts was measured by
ELISA. In the Mexican (derivation) cohort, MMP28 was found significantly increased in IPF






Gender (M/F) 66/16 14/55 <0.0001




FVC (% predicted) 74 ± 20 61 ± 28 0.0002
DLCO (% predicted) 54 ± 25 45 ± 28 0.06
SpO2 rest (%) 88 ± 6 85 ± 8 0.01
SpO2 exercise (%) 82 ± 7 79 ± 7 0.1
Meters (6MWT) 411 ± 156 328 ± 166 0.05
6MWT: Six-minute walk test. FVC: forced vital capacity, DLCO: diffusing capacity of the lung for carbon monoxide.
Performed in 63 IPF and 44 non-IPF patients at baseline. SpO2: oxygen saturation. Tests were performed at
2440mts of altitude. Numbers in age and functional tests are presented as average ± standard deviation.
https://doi.org/10.1371/journal.pone.0203779.t001
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(6.8 ± 4.2 ng/ml) versus fibrotic non-IPF (4.0 ± 3.8 ng/ml) and healthy controls (1.7 ± 1.9 ng/
ml) (ANOVA p<0.0001) (Fig 2, Blue). Similar results were obtained in the Spanish (valida-
tion) cohort IPF (7.1 ± 4.3 ng/ml) versus fibrotic non-IPF (4.7 ± 3.7 ng/ml) and controls
(2.5 ± 1.3 ng/ml) (ANOVA p<0.001) (Fig 2, Red). In the non-IPF group, no differences
between autoimmune diseases and chronic HP were found. The predictive performance of cir-
culating MMP28 for distinguishing patients with IPF from fibrotic non-IPF is shown in Fig 3.
The AUC of the Mexican cohort was 0.718 (95% CI, 0.635–0.800). With a cutoff point of 4.5
ng/mL of MMP28 in serum, the odds ratio was 5.32 (95%CI, 2.55–11.46), and the sensitivity
and specificity were 70.9% and 69% respectively. The positive predictive value was 73% and
the negative predictive value was 65%.
The AUC of the cohort from Spain was 0.690 (95% CI, 0.581–0.798). With a cutoff point of
4.5 ng/mL of MMP28 in serum, the odds ratio was 4.57 (95%CI, 1.76–12.04), and the sensitiv-
ity and specificity were 69.6% and 66.7% respectively. The positive predictive value was 66%
and the negative predictive value was 69%.
In both cohorts, MMP28 continued as a strong predictor of IPF diagnosis after logistic
regression analysis with the stepwise method (p = 0.003). Since recent data in mice suggest
that MMP28 may promote chronic lung inflammation and tissue remodeling induced by ciga-
rette smoke [19], we compared the serum levels of MMP28 between former- and never- ciga-
rette smokers irrespectively of their diagnosis taking together both cohorts (Mexico and
Spain). Our results showed that smokers had higher concentrations of MMP-28 (6.0 ± 4.3 ver-
sus non-smoker 5.0 ± 3.9, p = 0.04). However, when we compared the values in IPF and non-
IPF by smoking status separately no differences were found: (IPF smokers: 7.1 ± 4.7 ng/ml ver-
sus IPF non-smokers: 5.9 ± 3.1 ng/ml; p = 0.17. Non-IPF smokers: 3.9 ± 2.3 ng/ml versus non-
IPF non-smoker: 4.5 ± 4.2 ng/ml; p = 0.39).
IPF patients with UIP pattern on HRCT show higher MMP28 serum
concentration compared with non-IPF patients with UIP pattern
We then examined whether MMP28 levels may help to distinguish between definite UIP [1] in
the context of IPF versus non-IPF and possible UIP in the context of IPF versus non-IPF
(Table 3). Taken together both cohorts, we found that IPF patients with definite UIP pattern
showed significantly higher serum concentrations of MMP28 compared with non-IPF/UIP






Gender (M/F) 36/6 14/27 0.03




FVC (% predicted) 77 ± 20 86 ± 23 0.07
DLCO (% predicted) 50 ± 19 60 ± 21 0.02
SpO2 rest (%) 96 ± 2 97 ± 1.4 0.002
SpO2 exercise (%) 89 ± 5 91 ± 6 0.04
Meters (6MWT) 423 ± 75 425 ± 160 0.5
6MWT: Six-minute walk test. FVC: forced vital capacity. DLCO: diffusing capacity of the lung for carbon monoxide.
SpO2: oxygen saturation.
Tests were performed at an altitude of 18mts above sea level.
https://doi.org/10.1371/journal.pone.0203779.t002
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pattern (7.8 ± 4.4 versus 4.9 ± 4.4; p = 0.04). By contrast, no differences were observed when
IPF with possible UIP-pattern were compared (4.7 ± 3.2 versus 3.9 ± 3.0); p = 0.43).
Serum concentrations of MMP7 does not differentiate IPF from non-IPF
patients
Since it has been suggested that MMP-7 may also be useful for the differential diagnosis,
serum concentration of this enzyme was determined by ELISA in the derivation cohort. Our
Fig 1. Immunohistochemical localization of MMP28 in idiopathic pulmonary fibrosis, hypersensitivity pneumonitis and control lungs. Representative
photomicrographs of immunohistochemical staining performed with specific antibody against MMP28 in control lung tissue sections (panel A), IPF (panel B) and
HP (panel C). IHC negative controls were incubated with no primary antibody (panels D, E, F). A-F = 40X magnification (bar = 50μm).
https://doi.org/10.1371/journal.pone.0203779.g001
Fig 2. Distribution of MMP28 serum concentrations in IPF, non-IPF and healthy controls. Serum concentrations
(ng/ml) of MMP28 in the Mexican cohort (blue; ANOVA p<0.0001) and Spanish cohort (red; ANOVA p<0.001) are
significantly higher in patients with IPF. Averages are represented by horizontal lines.
https://doi.org/10.1371/journal.pone.0203779.g002
MMP28 as biomarker for IPF diagnosis
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results showed that this enzyme is similarly increased in IPF (10.24 ±5.7 ng/mL, n = 64) and in
non-IPF (8.5 ± 5.3 ng/mL, n = 48), and both are significantly higher than healthy controls
(2.1 ± 2.8ng/mL, n = 25; ANOVA p<0.001). We plotted MMP7 and MMP28 in a scattergram
and the correlation coefficient showed that the values were significantly correlated with each
other in IPF (rho = 0.5937; p<0.0001; S1 Fig). By contrast, only a marginal correlation was
found in non-IPF patients (rho = 0.319; p = 0.05).
Correlation between serum MMP28 and pulmonary function tests
The comparison of the concentration levels of MMP28 and diffusing capacity of the lungs for
carbon monoxide (DLCO; % predicted) is shown in Fig 4. Taken together both cohorts, base-
line serum MMP28 concentration demonstrated a marginal but significant negative correla-
tion with DLCO. By contrast, no correlation with forced vital capacity (FVC; % predicted) was
found.
Discussion
IPF is a devastating life-threatening disease that represents one of the major clinical challenges
because of its usual progressive nature and because it shares morphological and tomographic
UIP-like similarities with other chronic fibrotic lung disorders making difficult the differential
diagnosis.
The diagnostic uncertainty represents an important clinical problem since the therapeutic
approach is currently completely different. Thus, two drugs nintedanib and pirfenidone were
recently approved specifically for the treatment of IPF,[20,21] while corticosteroids and
Fig 3. Receiver operating characteristics curve analysis of serum MMP28 for discriminating IPF from non-IPF
disease in Mexican (derivation cohort, A) and Spanish cohort (validation cohort, B).
https://doi.org/10.1371/journal.pone.0203779.g003








The data represent the HRCT findings of both cohorts.
IPF patients with inconsistent HRCT were diagnosed by biopsy. All IPF and non-IPF patients were diagnosed by a
multidisciplinary diagnostic team.
HRCT from six non-IPF patients were not available.
https://doi.org/10.1371/journal.pone.0203779.t003
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immunosuppressive drugs are indicated in inflammatory and autoimmune-driven ILDs.
Moreover, the use of these drugs in IPF is not only useless but dangerous.[22]
In this context, the detection of biomarkers associated with IPF is a promising approach to
improve diagnostic accuracy and to overcome the difficulties of current diagnostic strategies.
In the last 10 years, a number of possible biomarkers have been evaluated but most of them
appear to predict outcome and have been associated primarily to disease progression and
worse survival. These biomarkers include Krebs von den lungen-6 antigen (KL-6), surfactant
protein A (SP-A), SP-D, matrix metalloproteinase (MMP)-1, MMP7, lysyl oxidase-like 2
(LOXL2), CC chemokine ligand 18 (CCL18), insulin-like growth factor binding protein-2
(IGFBP-2), heat shock protein 70 (HSP70), periostin, C-X-C motif chemokine 13 (CXCL-13),
and neoepitopes from extracellular matrix degradation among others.[23–25] Also, IPF
patients displaying an increase of some circulating T-lymphocyte subsets or with an exagger-
ated shortening leucocyte telomere length have increased risk for clinical deterioration and
death.[26,27]
However, biomarkers as a tool for the differential diagnosis of IPF with other fibrotic lung
disorders are scanty. To date, MMP7 alone or in combination with other molecules seems to
have the potential to discriminate IPF versus non-IPF patients.[10–12] For example, the com-
bination of plasma SP-D, MMP7, and osteopontin was recently demonstrated to enhance diag-
nostic accuracy to distinguish IPF from other idiopathic interstitial pneumonias, but
Fig 4. Spearman correlation between diffusing capacity of the lung for carbon monoxide (DLCO) % predicted, and the serum levels
of MMP28. The correlation was performed including IPF and non-IPF subjects from both cohorts which had baseline DLCO (n = 190).
The superimposed line represents the perfect correlation (Rho = 1) and the circles represent the dispersion of the cases. Rho -0.16;
p = 0.02.
https://doi.org/10.1371/journal.pone.0203779.g004
MMP28 as biomarker for IPF diagnosis
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importantly not with rheumatoid arthritis-associated ILD.[12] In addition, patients with
chronic HP, another frequent IPF-mimicking disease, were not included.
In the present study, we explored the role of MMP28 as a putative diagnostic biomarker.
This enzyme was selected because as we have recently shown, it is increased in IPF where it
may play a profibrotic role increasing the proliferative and migratory phenotype of epithelial
cells in a catalytic dependent manner.[18] Likewise, increased expression and release of
MMP28 has been reported in hypertrophic scars.[28] Importantly, there is some evidence sug-
gesting that MMP28 induces a coordinated TGF-β-dependent program leading to epithelial to
mesenchymal transition, a biological process that has been implicated in the pathogenesis of
IPF.[2, 18, 29]
We developed and validated the role of MMP28 as a new biomarker-based for the differen-
tial diagnosis of IPF. Specifically, we explored, and we found that the concentration of this
metalloprotease in serum is able to distinguish IPF from chronic HP and fibrotic ILD associ-
ated to autoimmune diseases. Clinically, both groups are probably the most important targeted
cohorts for using diagnostic biomarkers since they are the most likely to show a UIP-like pat-
tern but the therapeutic approach is completely different. This result was demonstrated in two
different cohorts of patients indicating that MMP28 levels over 4.5 ng/mL markedly increase
the odds of an IPF diagnosis. Taken together both cohorts, ROC curve analysis showed that
MMP28 is a useful marker for discriminating IPF from fibrotic non-IPF patients. The AUC of
0.718 in the derivation cohort and 0.690 in the validation cohort further indicated that this
enzyme is predictive of IPF with high sensitivity and specificity. Interestingly, when we com-
pared the serum concentration of MMP28 in the context of the radiological pattern, we found
that the levels of this enzyme were higher in IPF patients with UIP pattern compared with
non-IPF patients with the same pattern, while no differences were observed when we com-
pared possible UIP. This finding suggests that although IPF and non-IPF UIP patterns repre-
sent a similar radiologic (and morphologic) phenotype, the different pathogenic mechanisms
result in the expression/secretion of different molecules.
As previously mentioned MMP-7 has been suggested to be a useful biomarker to differenti-
ate IPF from non-IPF patients [10–12]. In this context, we also examined the serum concentra-
tions of this enzyme in the derivation cohort. Although, MMP7 was markedly higher in both
groups compared with controls, in contrast to our results with MMP28, MMP7 did not dis-
criminate between IPF and non-IPF patients.
In summary, our findings indicate that MMP28 improves diagnostic certainty of IPF and
might be included in the diagnostic models of the disease.
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5. Morell F, Villar A, Montero MÁ, Muñoz X, Colby TV, Pipvath S, et al. Chronic hypersensitivity pneumoni-
tis in patients diagnosed with idiopathic pulmonary fibrosis: a prospective case-cohort study. Lancet
Respir Med. 2013; 1: 685–694. https://doi.org/10.1016/S2213-2600(13)70191-7 PMID: 24429272
6. Pardo A, Cabrera S, Maldonado M, Selman M. Role of matrix metalloproteinases in the pathogenesis of
idiopathic pulmonary fibrosis. Respir Res. 2016; 17: 23. https://doi.org/10.1186/s12931-016-0343-6
PMID: 26944412
7. Zuo F, Kaminski N, Eugui E, Allard J, Yakhini Z, Ben-Dor A, et al. Gene expression analysis reveals
matrilysin as a key regulator of pulmonary fibrosis in mice and humans. Proc Natl Acad Sci. USA 2002;
99: 6292–6297. https://doi.org/10.1073/pnas.092134099 PMID: 11983918
8. Yu G, Kovkarova-Naumovski E, Jara P, Parwani A, Kass D, Ruiz V, Lopez-Otı́n C, et al. Matrix metallo-
proteinase-19 is a key regulator of lung fibrosis in mice and humans. Am J Respir Crit Care Med. 2012;
186: 752–762. https://doi.org/10.1164/rccm.201202-0302OC PMID: 22859522
9. Pardo A, Selman M, Kaminski N. Approaching the degradome in idiopathic pulmonary fibrosis. Int J Bio-
chem Cell. Biol. 2008; 40: 1141–1155. https://doi.org/10.1016/j.biocel.2007.11.020 PMID: 18207447
10. Rosas IO, Richards TJ, Konishi K, Zhang Y, Gibson K, Lokshin AE, et al. MMP1 and MMP7 as potential
peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med. 2008; 5: e93. https://doi.org/
10.1371/journal.pmed.0050093 PMID: 18447576
11. Morais A, Beltrão M, Sokhatska O, Costa D, Melo N, Mota P, et al. Serum metalloproteinases 1 and 7 in
the diagnosis of idiopathic pulmonary fibrosis and other interstitial pneumonias. Respir Med. 2015; 109:
1063–1068. https://doi.org/10.1016/j.rmed.2015.06.003 PMID: 26174192
12. White ES, Xia M, Murray S, Dyal R, Flaherty CM, Flaherty KR, et al. Plasma Surfactant Protein-D,
Matrix Metalloproteinase-7, and Osteopontin Index Distinguishes Idiopathic Pulmonary Fibrosis from
Other Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med. 2016; 194: 1242–1251. https://
doi.org/10.1164/rccm.201505-0862OC PMID: 27149370
13. Marchenko GN, Strongin AY. MMP28, a new human matrix metalloproteinase with an unusual cyste-
ine-switch sequence is widely expressed in tumors. Gene 2001; 265: 87–93. PMID: 11255011
MMP28 as biomarker for IPF diagnosis
PLOS ONE | https://doi.org/10.1371/journal.pone.0203779 September 12, 2018 10 / 11
14. Momohara S, Okamoto H, Komiya K, Ikari K, Takeuchi M, Tomatsu T, et al. Matrix metalloproteinase
28/epilysin expression in cartilage from patients with rheumatoid arthritis and osteoarthritis. Arthritis
Rheum. 2004; 50: 4074–4075. https://doi.org/10.1002/art.20799 PMID: 15593191
15. Jian P, Yanfang T, Zhuan Z, Jian W, Xueming Z, Jian N. MMP28 (epilysin) as a novel promoter of inva-
sion and metastasis in gastric cancer. BMC Cancer 2011; 11: 200. https://doi.org/10.1186/1471-2407-
11-200 PMID: 21615884
16. Ma Y, Halade GV, Zhang J, Ramirez TA, Levin D, Voorhees A, et al. Matrix metalloproteinase-28 dele-
tion exacerbates cardiac dysfunction and rupture after myocardial infarction in mice by inhibiting M2
macrophage activation. Circ Res. 2013; 112: 675–688. https://doi.org/10.1161/CIRCRESAHA.111.
300502 PMID: 23261783
17. Liu CL, Shen DL, Zhu K, Tang JN, Wang XF, Zhang L, et al. Characterization of interleukin-33 and
matrix metalloproteinase-28 in serum and their association with disease severity in patients with coro-
nary heart disease. Coron Artery Dis. 2014; 25: 498–504. https://doi.org/10.1097/MCA.
0000000000000117 PMID: 24710352
18. Maldonado M, Salgado-Aguayo A, Herrera I, Cabrera S, Ortiz-Quintero B, Staab-Weijnitz CA, Eickel-
berg O, Ramı́rez R, Manicone AM, Selman M, Pardo A. Upregulation and nuclear location of MMP28 in
alveolar epithelium of idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol. 2018; 59: 77–86. https://
doi.org/10.1165/rcmb.2017-0223OC PMID: 29373068
19. Manicone AM, Gharib SA, Gong KQ, Eddy WE, Long ME, Frevert CW, Altemeier WA, Parks WC,
Houghton AM. Matrix Metalloproteinase-28 is a key contributor to emphysema pathogenesis. Am J
Pathol 2017; 187:1288–1300. https://doi.org/10.1016/j.ajpath.2017.02.008 PMID: 28399390
20. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of ninteda-
nib in idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370: 2071–2082. https://doi.org/10.1056/
NEJMoa1402584 PMID: 24836310
21. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3
trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370: 2083–2092.
https://doi.org/10.1056/NEJMoa1402582 PMID: 24836312
22. Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ, Idiopathic Pulmonary Fibrosis Clinical
Research Network. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J
Med. 2012; 366: 1968–1977. https://doi.org/10.1056/NEJMoa1113354 PMID: 22607134
23. Guiot J, Moermans C, Henket M, Corhay JL, Louis R. Blood Biomarkers in Idiopathic Pulmonary Fibro-
sis. Lung 2017; 195: 273–280. https://doi.org/10.1007/s00408-017-9993-5 PMID: 28353114
24. Ley B, Brown KK, Collard HR. Molecular biomarkers in idiopathic pulmonary fibrosis. Am J Physiol Lung
Cell Mol Physiol. 2014; 307: L681–691. https://doi.org/10.1152/ajplung.00014.2014 PMID: 25260757
25. Borensztajn K, Crestani B, Kolb M. Idiopathic pulmonary fibrosis: from epithelial injury to biomarkers—
insights from the bench side. Respiration 2013; 86: 441–452. https://doi.org/10.1159/000357598
PMID: 24356558
26. Gilani SR, Vuga LJ, Lindell KO, Gibson KF, Xue J, Kaminski N, et al. CD28 down-regulation on circulat-
ing CD4 T-cells is associated with poor prognoses of patients with idiopathic pulmonary fibrosis. PLoS
One 2010; 5: e8959. https://doi.org/10.1371/journal.pone.0008959 PMID: 20126467
27. Stuart BD, Lee JS, Kozlitina J, Noth I, Devine MS, Glazer CS, et al. Effect of telomere length on survival
in patients with idiopathic pulmonary fibrosis: an observational cohort study with independent validation.
Lancet Respir Med. 2014; 2: 557–565. https://doi.org/10.1016/S2213-2600(14)70124-9 PMID:
24948432
28. Renò F, Sabbatini M, Stella M, Magliacani G, Cannas M. Effect of in vitro mechanical compression on
Epilysin (matrix metalloproteinase-28) expression in hypertrophic scars. Wound Repair Regen. 2005;
13: 255–261. https://doi.org/10.1111/j.1067-1927.2005.130307.x PMID: 15953044
29. Illman SA, Lehti K, Keski-Oja J, Lohi J. Epilysin (MMP28) induces TGF-beta mediated epithelial to mes-
enchymal transition in lung carcinoma cells. J Cell Sci. 2006; 119: 3856–3865. https://doi.org/10.1242/
jcs.03157 PMID: 16940349
MMP28 as biomarker for IPF diagnosis
PLOS ONE | https://doi.org/10.1371/journal.pone.0203779 September 12, 2018 11 / 11
